# Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)

Study · id `cardio:ct-nct02966717` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02966717](<https://clinicaltrials.gov/study/NCT02966717>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02966717

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

## Technical summary

Registry record NCT02966717. Randomized; no masking; primary purpose treatment. Start 2016-08 (registry gives no type); primary completion 2016-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT02966717, source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)
- Start date: 2016-08 (registry gives no type) (ClinicalTrials.gov record NCT02966717, source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)
- Primary completion: 2016-10 (actual) (ClinicalTrials.gov record NCT02966717, source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)
- Completion: 2021-10 (anticipated) (ClinicalTrials.gov record NCT02966717, source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02966717, source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02966717-2016-11-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
- Acronym: CKD
- Condition: Renal Insufficiency, Chronic
- Condition: Nephrotic Syndrome
- Intervention (Drug): Rituximab
- Intervention (Drug): conventional therapy
- Intervention (Drug): Mesenchymal stem cells
- Lead sponsor: Zhujiang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Zhujiang Hospital (`cardio:org-zhujiang-hospital`)

## Provenance

Content hash: 63cf68fa60b0f37e56f6a894d5ed9ef6d4f330abbf1ef4d453eb13627ac485a1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
